U.S. Markets closed

Adamas Pharmaceuticals, Inc. (ADMS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.2900-0.0600 (-1.38%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close4.3500
Open4.3000
Bid4.3100 x 1200
Ask4.4800 x 900
Day's Range4.2100 - 4.4640
52 Week Range1.9000 - 7.4500
Volume69,145
Avg. Volume231,396
Market Cap122.353M
Beta (5Y Monthly)2.57
PE Ratio (TTM)N/A
EPS (TTM)-2.2120
Earnings DateNov 05, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.19
  • Adamas announces changes to its Board of Directors with the appointment of Spyros Papapetropoulos and the retirement of Ivan Lieberburg
    GlobeNewswire

    Adamas announces changes to its Board of Directors with the appointment of Spyros Papapetropoulos and the retirement of Ivan Lieberburg

    EMERYVILLE, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the appointment of Spyros Papapetropoulos, MD, PhD, to its Board of Directors. Spyros brings more than 20 years of academic and industry experience with a focus on neurology, and previously held R&D and scientific leadership roles at Acadia, Cavion, Teva, Pfizer, Allergan, and Biogen. Additionally, Adamas announced the retirement of Ivan Lieberburg, MD, PhD from the Adamas board. “I would like to sincerely thank Ivan for his dedicated service to Adamas since 2004. He played a critical role through multiple successful NDA submissions and our evolution into a successful commercial organization. We wish him well,” said David L. Mahoney, Chairman, Adamas. “We are pleased to have Spyros join us at this next stage of growth. As a seasoned research and development leader, he will be an outstanding addition to our board.”“Spyros’ extensive experience within neurodegenerative diseases and movement disorders, along with his track record of bringing meaningful therapies to market ideally position him to bring an important perspective to the board. I look forward to his contributions as we continue to deliver on our mission for patients and unlock shareholder value,” added Neil F. McFarlane, CEO.“I am delighted to join Adamas at this exciting time in the journey towards being a leading neurology company,” said Spyros Papapetropoulos. “I very much look forward to being part of the company’s future growth and continued success.”Throughout his career, Spyros has led multiple pharmaceutical development programs resulting in successful regulatory filings and product launches. Spyros is a board-certified Neurologist trained in London, UK, and has authored more than 160 peer-reviewed publications. Additionally, Spyros has served on various U.S. government and non-profit committees on healthcare and biomedical research innovation.About Adamas At Adamas, our vision is clear – to deliver innovative medicines that reduce the burden of neurological diseases on patients, caregivers, and society. We are a fully integrated company focused on growing a portfolio of therapies to address a range of neurological diseases. For more information, please visit www.adamaspharma.com.Contact:Media: Sarah Mathieson Vice President, Corporate Communications 510-450-3528 smathieson@adamaspharma.comInvestors: Peter Vozzo Managing Director, Westwicke 443-213-0505 peter.vozzo@westwicke.com

  • Adamas to Present at Upcoming Piper Sandler Conference
    GlobeNewswire

    Adamas to Present at Upcoming Piper Sandler Conference

    EMERYVILLE, Calif., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, the Company’s Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference being held December 1-3, 2020. A replay of the pre-recorded fireside chat will be available beginning November 23, 2020 in the investor relations section of the Adamas website at http://ir.adamaspharma.com/events-presentations. The replay will be available for 30 days.About Adamas Pharmaceuticals, Inc. At Adamas our vision is clear – to deliver innovative medicines that reduce the burden of neurological diseases on patients, caregivers and society. We are a fully integrated company focused on growing a portfolio of therapies to address a range of neurological diseases. For more information, please visit www.adamaspharma.com.ContactMedia: Sarah Mathieson Vice President, Corporate Communications 510-450-3528 smathieson@adamaspharma.com Investors: Peter Vozzo Managing Director, Westwicke 443-213-0505 peter.vozzo@westwicke.com

  • Adamas Announces New Employment Inducement Grant
    GlobeNewswire

    Adamas Announces New Employment Inducement Grant

    EMERYVILLE, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted three new employees the option to purchase an aggregate of 45,000 shares of the company’s common stock, at a per share exercise price of $3.45, the closing trading price on November 6, and restricted stock units to acquire 22,500 shares of the company’s common stock. The stock options and restricted stock units vest over four years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the company. About Adamas Pharmaceuticals, Inc.  At Adamas our vision is clear – to deliver innovative medicines that reduce the burden of neurological diseases on patients, caregivers and society. We are a fully integrated company focused on growing a portfolio of therapies to address a range of neurological diseases. For more information, please visit www.adamaspharma.com.Contact:Investors: Peter Vozzo Westwicke Partners 443-213-0505 peter.vozzo@westwicke.comMedia: Sarah Mathieson Vice President, Communications & Engagement 510-450-3528 smathieson@adamaspharma.com